Stemline  Has What It Takes On EU Fast-Track Front  

There's good news for Stemline Therapeutics on the EU fast-track front. At least three other companies, though, have had their requests rejected in recent months and Novartis is not saying whether a request it made was successful or not.

PS1812_Speed Skater_332089994_1200.jpg
Speed matters when it come to drug evaluation • Source: Shutterstock

More from Europe

More from Geography